Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Pediatr Ophthalmol Strabismus ; 57: e38-e40, 2020 Jun 23.
Artigo em Inglês | MEDLINE | ID: mdl-32579685

RESUMO

The authors report a rare case of persistent fetal vasculature (PFV) associated with lens subluxation, axial myopia, and a thick bifid vascular stalk connecting the lens to an anomalous disc, along with medullated nerve fibers temporal to the disc. A thick fibrous membrane encasing the subluxated lens with multiple branch-like fibrovascular channels extending to the zonules was noted. This membrane with its extensions had similar histology as that of the PFV stalk. This case report adds to the understanding of PFV spectrum. [J Pediatr Ophthalmol Strabismus. 2020;57:e38-e40.].


Assuntos
Anormalidades do Olho/diagnóstico , Diagnóstico Diferencial , Humanos , Recém-Nascido , Subluxação do Cristalino/diagnóstico , Miopia/diagnóstico , Vítreo Primário Hiperplásico Persistente/diagnóstico
2.
Indian J Physiol Pharmacol ; 60(3): 282-90, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-29957984

RESUMO

Purpose: This study was conducted to evaluate the pharmacological interventions to target vascular proliferation in the Retinopathy of Prematurity (ROP). Methods: Protein Kinase C modulator (Bryostatin), tubulin polymerization inhibitor (Dolastatin 10), antiVEGF (Bevacizumab) and a non-specific VEGF inhibitor (Thalidomide) were screened in Retinopathy of Prematurity (ROP) model. The retinal vasculature was evaluated by calculating the tortuosity indices of vessels and electroretinography responses in terms of 'b' wave amplitude and was recorded from ROP rats on postnatal Day 17 and Day 25. Results: Retinopathy was seen in the form of tortousity of vessels at the posterior pole with arteries being affected more than veins. Maximum reduction in tortousity of vessels and the highest 'b' wave amplitude noted in bryostatin with a significant correlation between the two. Conclusion: Bryostatin showed a potential anti-angiogenic effect on the progression of ROP and may hold a promising future in the treatment of ROP.


Assuntos
Bevacizumab/uso terapêutico , Briostatinas/uso terapêutico , Depsipeptídeos/uso terapêutico , Oxigênio/toxicidade , Retinopatia da Prematuridade/tratamento farmacológico , Talidomida/uso terapêutico , Adjuvantes Imunológicos/uso terapêutico , Inibidores da Angiogênese/uso terapêutico , Animais , Animais Recém-Nascidos , Hiperóxia , Ratos , Ratos Wistar , Moduladores de Tubulina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...